Αναφορές – References
|
- Demopoulos CA, Pinckard RN, Hanahan DJ (1979), Platelet-activating Evidence for1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators, Journal of Biological Chemistry254(19),9355-8.
- Shindou , Nakanishi H.,Harayama T.,Taguchi S.,ShimizuT.(2007) A Single Enzyme Catalyzes Both Platelet-activating FactorProduction and Membrane Biogenesis of Inflammatory Cells: Cloning and Characterization of ACETYL-CoA: LYSO-PAFACETYLTRANSFERASE,JBC 282(9),6532-6539. https://www.sciencedirect.com/science/articl e/pii/S0021925820522631#!
- Tselepis D., Chapman M.J. (2002) Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl.3, 57–68.
- Rosenson S., Stafforini D.M. (2012) Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J. Lipid Res.,53,1767– 1782
- Bochkov V., Gesslbauer B., Mauerhofer C., Philippova , Erne P., Oskolkova O.V. (2017) Pleiotropic effects of oxidizedphospholipids. Free Radic. Biol. Med.111, 6– 24.
- Bochkov V.N., Oskolkova O.V., Birukov K.G., Levonen A.-L., Binder C.J., Stöckl J. (2010) Generation and biological activities ofoxidized Antioxid. Redox Signal. 12,1009–1059.
- Bochkov V.N. (2007) Inflammatory profile of oxidized Thromb. Haemost. 97,348.
- Fu , Birukov K.G. (2009) Oxidized phospholipids in control of inflammation and endothelial barrier. Transl. Res.153, 166– 176.
- Spinas E., Kritas S.K., Saggini A., Mobili A., Caraffa A., Antinolfi P., Pantalone A., Tei M., Speziali A., Saggini R. (2014) Role of mast cells in atherosclerosis: A classical inflammatory disease. J. Immunopathol. Pharmacol.27,517–521.
- Brailoiu , Barlow C.L., Ramirez S.H., Abood M.E., Brailoiu G.C. (2018) Effects of platelet-activating factor on brainmicrovascular endothelial cells. Neuroscience 377,105–113.
- Bellizzi J., Geathers J.S., Allan K.C., Gelbard H.A. (2016) Platelet-activating factor receptors mediate excitatory postsynaptichippocampal injury in experimental autoimmune encephalomyelitis. J. Neurosci.36,1336–1346
- Briones M.R.S., Snyder A.M., Ferreira R.C., Neely E.B., Connor J.R., Broach J.R. (2018) A possible role for platelet-activating factor receptor in amyotrophic lateral sclerosis Front.Neurol.9, https://doi.org/10.3389/fneur.2018.00039
- Camussi G. (1986) Potential role of platelet- activating factor in renal Kidney Int. 29,469–477
- Fragopoulou E., Iatrou C., Demopoulos C.A. (2005) Characterization of acetyl-Coa: Lyso- paf acetyltransferase of humanmesangial Mediat. Inflamm. 263–272
- Plante E., Hebert R.L., Lamoureux C., Braquet P., Sirois P. (1986) Hemodynamic effects of paf-acether. Pharm. Res.Commun. 18,173–179
- Melnikova O., Villares G.J., Bar-Eli M. (2008) Emerging roles of PAR-1 and PAFR in melanoma metastasis. CancerMicroenviron.1,103–111.
- Melnikova O., Bar-Eli M. (2009) Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 22,257–267
- Sahu R.P., Harrison K.A., Weyerbacher J., Murphy C., Konger R.L., Garrett J.E., Chin-Sinex H.J., Johnston M.E., DynlachtJ.R., Mendonca M. (2016) Radiation therapy generates platelet-activating factor agonists. Oncotarget. 7,20788–20800.
- Da Silva-Jr , Chammas R., Lepique A., Jancar S. (2017) Platelet-activating factor (PAF) receptor as a promising target forcancer cell repopulation after radiotherapy. Oncogenesis. 6, e296.
- Denizot Y, Chianéa T, Labrousse F, Truffinet V, Delage M, Mathonnet M. (2005) Platelet- activating factor and human thyroid cancer. Eur J Endocrinol. 153(1),31–40
- Denizot Y, Desplat V, Drouet M, Bertin F, Melloni B. (2001) Is there a role of platelet- activating factor in human lung cancer? Lung 33(2),195–202
- Hackler PC, Reuss S, Konger RL, Travers JB, Sahu (2014) Systemic platelet- activating factor receptor activationaugments experimental lung tumor growth and metastasis. Cancer Growth Metastasis. 7, S14501.
- Palgan , Bartuzi Z. (2015) Platelet activating factor in allergies. Int. J. Immunopathol. Pharmacol. 28,584–589.
- Farbman , Michelson K. (2016) Anaphylaxis in Children Curr Opin Pediatr. 28(3), 294–297.
- Trapali M., Mavri-Vavayanni M., Siafaka A. (1996) PAF acetylhydrolase activity and PAF levels in pancreas and plasma of diabetic, fasted and well-fed rat. Life Sciences 59(10), 849-857
- Phenekos C, Siafaka A., Trapali M., Botitsi , Mavri M. (1992) Effect of gliclazide on PAF induced platelet aggregation in patients with non-insulin dependent Diabetes Mellitus metabolism. 41(5),30-32
- Ersoy B., Huseyinov A., Darcan (2005) The role of platelet-activating factor in pathogenesis of type 1 diabetes. Diabetes Care.28,980
- Kudolo G.B., DeFronzo R.A. (1999) Urinary platelet-activating factor excretion is elevated in non-insulin dependent diabetes mellitus. Prostaglandins Another Lipid Mediat. 57,87–
- Liu R., Xia S.H. (2006) Role of platelet- activating factor in the pathogenesis of acute pancreatitis. World J. Gastroenterol.12,539– 545.
- Karidis N.P., Kouraklis G., Theocharis S.E. (2006) Platelet-activating factor in liver injury: A relational scope. World J. Gastroenterol. 12,3695–3706.
- Frost B.L., Caplan M.S. (2013) Necrotizing enterocolitis: Pathophysiology, platelet- activating factor, and Semin.Pediatr. Surg. 22,88–93
- Nitoda E., Moschos M.M., Mavragani C.P., Koutsilieris (2012) Ocular actions of platelet-activatingfactor: Clinical implications.Expert Opin. Ther. Targets. 16,1027–1039.
- Hikiji , Takato T., Shimizu T., Ishii S. (2008) The roles of prostanoids, leukotrienes, and platelet-activating factorin bonemetabolism and disease Progress in Lipid Research 47, 107–126
- Yin -J., Chen Z.-Y., Zhu X.-N., Hu J.-J. (2017) Loss of PAFR prevents neuroinflammation and brain dysfunction aftertraumatic brain injury. Sci. Rep. 7,40614.
|
|